NCT00761436 is a Phase 2 clinical trial of Spheramine (BAY86-5280) in Parkinson''s Disease, sponsored by Bayer.

Who is sponsoring NCT00761436?

NCT00761436 is sponsored by Bayer.

What drugs are being tested in NCT00761436?

Interventions in NCT00761436: Spheramine (BAY86-5280).

What condition does NCT00761436 study?

NCT00761436 studies Parkinson''s Disease.

Is NCT00761436 still recruiting?

NCT00761436 is currently terminated. Last updated 8 April 2021.

Last reviewed 2021-04-08 · How we verify

NCT00761436

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Safety and Efficacy of Spheramine

Terminated Phase 2 Last updated 8 April 2021

What this trial tests

Phase 2 trial testing Spheramine (BAY86-5280) in Parkinson''s Disease in 6 participants. Terminated before completion.

Timeline

29 February 2000

Primary endpoint
14 May 2012

14 May 2012

Quick facts

Lead sponsor	Bayer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	29 February 2000
Primary completion	14 May 2012
Estimated completion	14 May 2012
Sites	1 location across United States

Drugs / interventions tested

Spheramine (BAY86-5280) — full drug profile →

Conditions studied

Parkinson''s Disease — all drugs for Parkinson''s Disease →

Sponsor

Bayer — full company profile →

Who can join

Adults 40 to 70, any sex, with Parkinson''s Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tolerability and Efficacy of Spheramine will be evaluated after operative implantation (Stereotactic Intrastriatal Implantation) in patients with advanced Parkinson's Disease

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Spheramine (BAY86-5280)

Trials testing the same drug.

NCT00206687 — STEPS Trial - Spheramine Safety and Efficacy Study · Phase 2 · terminated

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00761436 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 8 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00761436.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing